Nevirapine

INDICATIONS

FDA

  • Treatment of HIV infection in combination with other antiretroviral agents.
  • Due to the increased risk of hepatitis, avoid starting NVP in women with pre-treatment CD4 >250 and men with CD4 >400.

NON-FDA APPROVED USES

  • Single dose at the time of delivery to prevent perinatal transmission (widely used in developing countries, but the risk of NNRTI resistance; combination therapy preferred when available). The risk of hepatitis for women with CD4 >250 does not apply to single-dose NVP.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: October 10, 2023